AEterna Zentaris - Recruiting 18 years or older. - Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer..
Gynecologic Oncology Group - Recruiting 18 years or older. - A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma.
Gynecologic Oncology Group - Recruiting N/A or older. - A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus.
Novartis - Recruiting 18 years or older. - A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Randomized Phase II Study With Safety Lead-in to Assess the Antitumor Efficacy of the Mek Inhibitor Trametinib Alone or in Combination With GSK2141795, an Akt Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer.
Gynecologic Oncology Group - Recruiting N/A or older. - A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure.
University of Southern California - Recruiting 18 years to 35 years. - The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?.
Otsuka Novel Products GmbH - Recruiting 18 years or older. - A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma.
ARCAGY/ GINECO GROUP - Recruiting 18 years or older. - Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy.
Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older. - A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma.
PharmaMar - Recruiting 18 years to 75 years. - Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors.
Catholic University of the Sacred Heart - Recruiting 18 years or older. - A Randomized Phase II Trial of Carboplatin-Paclitaxel Compared to Carboplatin-Paclitaxel-Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer.
Radboud University - Recruiting 18 years or older. - A Phase Ib Study of Combination of Temsirolimus (Toriselr) and Pegylated Liposomal Doxorubicin (PLD, Doxilr/ Caelyxr) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy.
Korean Gynecologic Oncology Group - Recruiting 20 years to 75 years. - A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy in High-Risk Endometrial Cancer Patients After Operation..